Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14042453 | 0.76 | HDAC3 (0.51) | RAB9ANPC1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL14041817 | 0.73 | MMP1 (0.57) | RAB9ANPC1KMT2AMAOBSMN1; SMN2 | |
| Oxalic Acid SCHEMBL7569162 | 0.73 | KDM1A (0.41) | RAB9AGAAPOLBCES2CES1 | |
| SCHEMBL14041941 | 0.73 | MMP1 (0.58) | RAB9ANPC1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL10271980 | 0.72 | KDM1A (0.44) | RAB9ANPC1GAAKMT2AKDM1A | |
| SCHEMBL6258048 | 0.71 | KDM1A (0.47) | RAB9ANPC1GAAKDM1AMAOA | |
| SCHEMBL6254714 | 0.71 | KDM1A (0.47) | RAB9ANPC1GAAKDM1AMAOA | |
| SCHEMBL12281223 | 0.71 | ROCK2 (0.53) | RAB9ANPC1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL14042337 | 0.70 | PARP15 (0.46) | RAB9ANPC1KMT2ASMN1; SMN2EPHX2 | |
| SCHEMBL14041857 | 0.70 | ALDH1A1 (0.55) | RAB9ANPC1GAAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420566-B2 | NITRIC OXIDE SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | ALK, QDPR, CYP3A7 | RAB9A 3414/4885NPC1 2358/4885GAA 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.